What is Quantum BioPharma Ltd's earnings per share (EPS)?

Quantum BioPharma Ltd (QNTM) reported diluted earnings per share of $-8.20 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Quantum BioPharma Ltd Financials

QNTM

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Quantum BioPharma Ltd (QNTM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Quantum BioPharma Ltd passes 2 of 9 financial strength tests. 1 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.25x

For every $1 of reported earnings, Quantum BioPharma Ltd generates $0.25 in operating cash flow (-$6.9M OCF vs -$27.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$27.2M

Quantum BioPharma Ltd reported -$27.2M in net income in fiscal year 2025.

EPS (Diluted)

$-8.20

Quantum BioPharma Ltd earned $-8.20 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$6.9M

YoY+36.5%

Quantum BioPharma Ltd generated -$6.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 36.5% from the prior year.

Cash & Debt

$6.0M

YoY+117.5%

5Y CAGR+0.1%

Quantum BioPharma Ltd held $6.0M in cash against $619K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Quantum BioPharma Ltd had 12 shares outstanding in fiscal year 2025. This represents a decrease of 83.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-532.9%

5Y CAGR-425.1pp

Quantum BioPharma Ltd's ROE was -532.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

Quantum BioPharma Ltd invested $0 in capex in fiscal year 2025, funding long-term assets and infrastructure.

QNTM Income Statement

Metric	FY25	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	$19K+103.9%	$9K-9.8%	$10K-9.7%	$11K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$27.2M	N/A	-$23.6M+33.1%	-$35.3M-11.0%	-$31.8M+18.7%	-$39.1M
EPS (Diluted)	$-8.20	N/A	$-0.69+28.9%	$-0.97+58.9%	$-2.36	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.7M+51.4%	-$9.8M-11.7%	-$8.7M	N/A	-$4.0M-19.8%	-$3.4M-60.3%	-$2.1M	N/A
EPS (Diluted)	$-1.25+61.3%	$-3.23+8.5%	$-3.53	N/A	$-4.37-5362.5%	$-0.08+97.7%	$-3.43	N/A

QNTM Balance Sheet

Metric	FY25	FY23	FY22	FY21	FY20	FY19
Total Assets	$17.1M-2.0%	$17.5M-54.5%	$38.4M-39.0%	$63.0M+50.0%	$42.0M-2.9%	$43.2M
Current Assets	$12.1M+8.7%	$11.1M-37.9%	$17.9M-61.1%	$45.9M+71.0%	$26.9M+213.9%	$8.6M
Cash & Equivalents	$6.0M+117.5%	$2.8M-83.8%	$17.0M-51.8%	$35.3M+101.2%	$17.5M+193.7%	$6.0M
Inventory	$117K	$0	N/A	N/A	$0-100.0%	$709K
Accounts Receivable	N/A	N/A	$374K-25.3%	$501K+210.5%	$161K-89.6%	$1.6M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.7M+46.3%	$4.6M-42.0%	$7.9M-10.9%	$8.8M+56.1%	$5.7M-18.5%	$6.9M
Current Liabilities	$6.7M+46.3%	$4.6M-41.7%	$7.8M-10.0%	$8.7M+55.9%	$5.6M-18.3%	$6.8M
Long-Term Debt	$619K	$0-100.0%	$38K-71.0%	$131K+65.6%	$79K-28.3%	$110K
Total Equity	$10.4M-19.1%	$12.9M-57.7%	$30.5M-43.6%	$54.1M+49.1%	$36.3M+0.1%	$36.3M
Retained Earnings	-$172.1M-9.0%	-$157.9M-9.5%	-$144.2M-14.3%	-$126.2M-38.8%	-$90.9M-53.8%	-$59.1M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$14.2M-7.5%	$15.3M+2.8%	$14.9M-13.1%	$17.1M-10.0%	$19.0M+24.8%	$15.2M	N/A	$17.5M
Current Assets	$9.3M-9.7%	$10.3M+4.1%	$9.9M-17.6%	$12.1M-12.9%	$13.8M+38.1%	$10.0M	N/A	$11.1M
Cash & Equivalents	$446K-70.2%	$1.5M-57.4%	$3.5M-41.3%	$6.0M+92.2%	$3.1M-5.6%	$3.3M+148.6%	$1.3M-51.8%	$2.8M
Inventory	$78K+1.0%	$77K-18.1%	$94K-19.9%	$117K	N/A	N/A	N/A	$0
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.6M-49.8%	$13.2M+28.1%	$10.3M+54.9%	$6.7M+81.4%	$3.7M-27.0%	$5.0M	N/A	$4.6M
Current Liabilities	$6.6M-49.8%	$13.2M+28.1%	$10.3M+54.9%	$6.7M	N/A	$5.0M	N/A	$4.6M
Long-Term Debt	$2.0M+1.6%	$1.9M+78.7%	$1.1M+75.7%	$619K	N/A	N/A	N/A	$0
Total Equity	$7.5M+266.7%	$2.0M-54.8%	$4.5M-56.6%	$10.4M-32.0%	$15.3M+50.4%	$10.2M-11.4%	$11.5M-10.8%	$12.9M
Retained Earnings	-$195.3M-2.8%	-$189.9M-5.1%	-$180.7M-5.0%	-$172.1M-3.2%	-$166.8M-2.3%	-$162.9M	N/A	-$157.9M

QNTM Cash Flow Statement

Metric	FY25	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$6.9M+36.5%	-$10.8M+61.8%	-$28.3M-36.6%	-$20.7M-8.4%	-$19.1M-39.5%	-$13.7M
Capital Expenditures	$0	$0-100.0%	$114K	$0	$0	N/A
Free Cash Flow	-$6.9M+36.5%	-$10.8M+61.9%	-$28.4M-37.1%	-$20.7M-8.4%	-$19.1M	N/A
Investing Cash Flow	-$1.5M-457.7%	-$270K-102.2%	$12.1M+4407.4%	$269K-95.9%	$6.5M+2921.3%	-$231K
Financing Cash Flow	$11.6M+471.6%	-$3.1M-51.1%	-$2.1M-105.4%	$38.2M+58.1%	$24.2M+502.6%	$4.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	-$1.7M+11.7%	-$1.9M+54.3%	-$4.3M-409.8%	-$836K+75.9%	-$3.5M-470.6%	-$606K+69.3%	-$2.0M-131.7%	-$852K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$408K+130.0%	-$1.4M-0.8%	-$1.4M-208.5%	$1.2M+135.9%	-$3.5M-569.2%	$738K+3434.3%	-$22K	$0
Financing Cash Flow	$261K-79.7%	$1.3M-58.8%	$3.1M+27.0%	$2.5M-63.4%	$6.7M+265.3%	$1.8M+224.4%	$569K+2355.3%	-$25K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

QNTM Financial Ratios

Metric	FY25	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-532.9%	N/A	-77.3%-12.1pp	-65.2%+22.4pp	-87.6%+20.3pp	-107.9%
Return on Assets	-243.7%	N/A	-61.5%-5.4pp	-56.0%+19.7pp	-75.8%+14.8pp	-90.5%
Current Ratio	1.80-0.6	2.43+0.1	2.28-3.0	5.28+0.5	4.82+3.6	1.25
Debt-to-Equity	0.06+0.1	0.000.0	0.000.0	0.000.0	0.000.0	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-63.2%+413.9pp	-477.1%-284.1pp	-193.0%	N/A	-26.2%+6.7pp	-32.9%-14.7pp	-18.2%	N/A
Return on Assets	-33.5%+30.3pp	-63.8%-5.1pp	-58.8%	N/A	-21.1%+0.9pp	-22.0%	N/A	N/A
Current Ratio	1.41+0.6	0.78-0.2	0.96-0.8	1.80	N/A	1.99	N/A	2.43
Debt-to-Equity	0.26-0.7	0.95+0.7	0.24+0.2	0.06-0.2	0.24-0.3	0.49	N/A	0.00
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Medicinova MNOV

$70.9M

Abvc Biopharma Inc ABVC

$27.9M

Pmv Pharmaceuticals, Inc. PMVP

$71.5M

Applied Therapeutics APLT

$14.9M

Precision Biosciences DTIL

$143.9M

Frequently Asked Questions

Is Quantum BioPharma Ltd profitable?

No, Quantum BioPharma Ltd (QNTM) reported a net income of -$27.2M in fiscal year 2025.

How much debt does Quantum BioPharma Ltd have?

As of fiscal year 2025, Quantum BioPharma Ltd (QNTM) had $6.0M in cash and equivalents against $619K in long-term debt.

What is Quantum BioPharma Ltd's return on equity (ROE)?

Quantum BioPharma Ltd (QNTM) has a return on equity of -532.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Quantum BioPharma Ltd's free cash flow?

Quantum BioPharma Ltd (QNTM) generated -$6.9M in free cash flow during fiscal year 2025. This represents a 36.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Quantum BioPharma Ltd's operating cash flow?

Quantum BioPharma Ltd (QNTM) generated -$6.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Quantum BioPharma Ltd's total assets?

Quantum BioPharma Ltd (QNTM) had $17.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Quantum BioPharma Ltd's capital expenditures?

Quantum BioPharma Ltd (QNTM) invested $0 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Quantum BioPharma Ltd have outstanding?

Quantum BioPharma Ltd (QNTM) had 12 shares outstanding as of fiscal year 2025.

What is Quantum BioPharma Ltd's current ratio?

Quantum BioPharma Ltd (QNTM) had a current ratio of 1.80 as of fiscal year 2025, which is generally considered healthy.

What is Quantum BioPharma Ltd's debt-to-equity ratio?

Quantum BioPharma Ltd (QNTM) had a debt-to-equity ratio of 0.06 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Quantum BioPharma Ltd's return on assets (ROA)?

Quantum BioPharma Ltd (QNTM) had a return on assets of -243.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Quantum BioPharma Ltd's cash runway?

Based on fiscal year 2025 data, Quantum BioPharma Ltd (QNTM) had $6.0M in cash against an annual operating cash burn of $6.9M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Quantum BioPharma Ltd's Piotroski F-Score?

Quantum BioPharma Ltd (QNTM) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Quantum BioPharma Ltd's earnings high quality?

Quantum BioPharma Ltd (QNTM) has an earnings quality ratio of 0.25x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.